Respiratory syncytial virus seasonality: A global overview
Obando-Pacheco, Pablo; Justicia-Grande, Antonio José; Rivero-Calle, Irene; Rodríguez-Tenreiro, Carmen; Sly, Peter; Ramilo, Octavio; Mejías, Asunción; Baraldi, Eugenio; Papadopoulos, Nikolaos G.; Nair, Harish; Nunes, Marta C.; Kragten-Tabatabaie, Leyla; Heikkinen, Terho; Greenough, Anne; Stein, Renato T.; Manzoni, Paolo; Bont, Louis; Martinón-Torres, Federico
(2018) Journal of Infectious Diseases, volume 217, issue 9, pp. 1356 - 1364
(Article)
Abstract
Respiratory syncytial virus (RSV) is the leading cause of acute lower respiratory infections in children. By the age of 1 year, 60%–70% of children have been infected by RSV. In addition, early-life RSV infection is associated with the development of recurrent wheezing and asthma in infancy and childhood. The need
... read more
for precise epidemiologic data regarding RSV as a worldwide pathogen has been growing steadily as novel RSV therapeutics are reaching the final stages of development. To optimize the prevention, diagnosis, and treatment of RSV infection in a timely manner, knowledge about the differences in the timing of the RSV epidemics worldwide is needed. Previous analyses, based on literature reviews of individual reports obtained from medical databases, have failed to provide global country seasonality patterns. Until recently, only certain countries have been recording RSV incidence through their own surveillance systems. This analysis was based on national RSV surveillance reports and medical databases from 27 countries worldwide. This is the first study to use original-source, high-quality surveillance data to establish a global, robust, and homogeneous report on global country-specific RSV seasonality.
show less
Download/Full Text
The full text of this publication is not available.
Keywords: Respiratory infections, Respiratory syncytial virus (RSV), RSV epidemiology, RSV seasonality, RSV surveillance, Immunology and Allergy, Infectious Diseases
ISSN: 0022-1899
Publisher: Oxford University Press
Note: Funding Information: Financial support. This work was partially supported by a research grant from NOVAVAX,Inc to ReSVinet, which was used to fund part of the field work. F. M. T.’s research time and activities have been supported by grants from Consellería de Sanidade, Xunta de Galicia, Instituto de Salud Carlos III (Intensificación de la actividad investigadora 2007–2017), Fondo de Investigación Sanitaria (FIS; PI070069/PI10005 40/PI1601569) del Plan Nacional de I + D + I and “fondos FEDER,” and 2016-PG071 Consolidación e Estructuración REDES 2016GI-1344 G3VIP (Grupo Gallego de Genética Vacunas Infecciones y Pediatría, ED341D R2016/021). Dr Bont has regular interaction with pharmaceutical and other industrial partners. He has not received personal fees or other personal benefits. UMCU has received major funding (> €100 000 per industrial partner) for investigator initiated studies from AbbVie, MedImmune, Janssen, the Bill and Melinda Gates Foundation and MeMed Diagnostics. UMCU has received minor funding participation in trials by Regeneron and Janssen since 2015 (total annual estimate less than €20 000). He received minor funding for consultation and invited lectures by AbbVie, MedImmune, Ablynx, Bavaria Nordic, MabXience, Novavax, Janssen (total annual estimate less than €20 000). Publisher Copyright: © The Author(s) 2018. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. Copyright: Copyright 2019 Elsevier B.V., All rights reserved.
(Peer reviewed)